Company Analysis

Decoy Therapeutics Inc. (DCOY)

Nasdaq: DCOY · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2014
Grade3.5
◀ Past 3.0● Present 4.1▶ Future 3.4
5 est.

Who runs Decoy Therapeutics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Mcvicar William K.
President and CEO. First filing Apr 2017, latest Sep 2, 2026, 2 filings in all.
Officers reporting now
5
of 10 people with a filing in the last fifteen months
Directors reporting now
5
30 people on the record since 2015
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Mcvicar William K.President and CEOApr 2017Sep 2, 2026none
Pierce Frederick IIChief Executive OfficerNov 2025Sep 2, 2026none
Rosenblum Mark JChief Financial OfficerSep 2019Sep 2, 2026none
Hibner Barbara LouiseChief Scientific OfficerNov 2025Sep 2, 2026none
Marschel Peter KlausChief Business OfficerNov 2025Sep 2, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Burleson TessdirectorJul 2019Sep 2, 2026none
Gauthier Patricia G.directorJul 2026Sep 2, 2026none
Hanish Arnold CdirectorJul 2019Sep 2, 20262 · $0.00
Lammers PauldirectorJul 2019Sep 2, 2026none
Lieber Jonathan IdirectorJun 2020Sep 2, 2026none
Earlier names on the record22, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton DCOY · research, not advice